Stay updated on Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0.
    Difference
    0.1%
    Check dated 2026-11-01T01:37:41.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces that federal agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    0.5%
    Check dated 2026-10-25T01:36:08.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The site revision identifier changes from v3.7.1 to v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-18T01:20:42.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov site footer revision changed from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-11T01:52:52.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The record history now shows a new revision tag v3.7.0 and removes the older v3.6.6, indicating a newer version of the study record has been published.
    Difference
    0.1%
    Check dated 2026-09-20T00:42:05.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    New revision entry v3.6.6 was added to the history, replacing the prior v3.6.5. This reflects a minor platform update to the page's revision history.
    Difference
    0.1%
    Check dated 2026-08-29T20:56:16.000Z thumbnail image

Stay in the know with updates to Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial page.